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Abstract More than 10 splice variants of the Fc receptor for
IgA (FcKR, CD89) have been identi¢ed in human myeloid cells.
In this study, we quanti¢ed FcKR splice transcripts vEC2 and
v66EC2, which lack the entire and a part of the homologous
immunoglobulin-like extracellular domain 2 (EC2), respectively.
Tumor necrosis factor-K was found to speci¢cally increase the
ratio of vEC2 to the wild type CD89 in neutrophils and con-
versely decrease the vEC2 ratio in monocytes. We also observed
a signi¢cant decrease in the neutrophil vEC2/CD89 ratio in
pneumonia patients. These results suggest that vEC2 is di¡er-
entially regulated and could be involved in immunoregulation of
IgA-mediated host defense.
1 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
IgA is the predominant immunoglobulin (Ig) in external
secretions of the mucosa. Human myeloid cells such as mono-
cytes/macrophages and neutrophils express the Fc receptor for
IgA (FcKR, CD89), and IgA-coated antigens trigger e¡ector
functions of these cells including phagocytosis, superoxide
production, in£ammatory cytokine release, and antibody-de-
pendent cell-mediated cytotoxicity [1]. Although its role in
mucosal immunoprophylaxis mechanisms is still poorly
understood, recent studies with transgenic mice expressing
human FcKR have provided direct evidence for FcKR func-
tion in host defense against bacterial infection [2,3].
The FcKR gene has been mapped to chromosome 19q13.4
[4], and consists of ¢ve exons spanning approximately 12 kb
[5] (Fig. 1). Exons S1 and S2 encode the leader peptide, EC1
and EC2 each encode a homologous Ig-like extracellular do-
main, and TM/C encodes the transmembrane domain and
cytoplasmic tail of the receptor. It has been reported so far
that a number of diverse mRNA isoforms of FcKR are gen-
erated by deleting the entire or a part of each exon via alter-
native RNA splicing [6^11]. Among them, transcript v66EC2,
which lacks 66 nucleotides in the portion encoding the EC2
domain, is expressed predominantly in alveolar macrophages
and is the only variant that has been identi¢ed as a natural
protein [7]. On the other hand, transcript vEC2 lacking the
entire EC2 domain has been identi¢ed in granulocytes and
monocytes [6^9], and Chinese hamster ovary cells transfected
with this variant have been demonstrated to bind secretory
IgA but not serum IgA, while transfectants expressing full-
length CD89 bind both [8].
The expression and function of FcKR are modulated by
lipopolysaccharide (LPS) [12] and several in£ammatory cyto-
kines, such as interleukin (IL)-1L, tumor necrosis factor-K
(TNFK), transforming growth factor-L (TGFL), and IL-8
[12^15]. In addition, altered FcKR expression has been re-
ported in allergic diseases [16], IgA nephropathy [17], HIV
infection [18], bacterial infection [19], alcoholic liver cirrhosis
[20], and ankylosing spondylitis [21]. While these reports sug-
gest an important role of FcKR in mucosal in£ammatory
diseases, our knowledge of expression of FcKR splice isoforms
in response to cytokines and in diseases has been poor. In this
paper, we conducted quantitative analyses of the splice var-
iants vEC2 and v66EC2 and demonstrated their di¡erential
expression in a cell type-speci¢c manner and in response to
TNFK. In addition, we observed an altered vEC2/CD89 ratio
in neutrophils of patients with pneumonia.
2. Materials and methods
2.1. Subjects
Blood samples were collected from 18 healthy volunteers and four
patients with pneumonia (all patients had Gram-negative bacteremia:
Klebsiella sp., Acinetobacter sp., Pseudomonas sp., and Gram negative
rod sp.). Septic shock and respiratory failure in patients with pneumo-
nia occurred within 72 h after hospitalization, and were con¢rmed by
microbiological and other laboratory tests. All the patients with pneu-
monia received antimicrobial chemotherapy; one patient was given
ceftazidine 1.0 g twice daily for 3 days and the remaining patients
were given imipenem/cilastatin sodium 0.5 g twice daily for 1 day.
Each blood specimen was taken from the patients immediately after
these treatments. None of the patients received corticosteroid and/or
immunosuppressive drug treatment. In Fig. 5, sex and age were
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matched between patients [three males and one female, ranging in age
from 64 to 75 (mean age 68.5M 5.9 yr)] and healthy subjects [¢ve
males and two females, ranging in age from 61 to 79 (mean age
69.4M 8.0 yr)]. Healthy subjects in other ¢gures were eight males
and three females, ranging in age from 20 to 49 (mean age
30.2M 8.6 yr). Informed consent was obtained from all healthy sub-
jects and patients.
2.2. Cell isolation
Neutrophils were isolated from heparinized peripheral blood by
Polymorphprep (Nycomed, Oslo, Norway) gradient centrifugation,
and the purity was greater than 95% as judged by Giemsa staining
(Di¡-Quik; Baxter, Dudingen, Switzerland); the remaining cells were
mainly erythrocytes and rarely eosinophils. Human peripheral blood
mononuclear cells (PBMC) were isolated by Lymphoprep (Nycomed)
gradient centrifugation. Monocytes were puri¢ed from PBMC by neg-
ative indirect selection using the magnetic cell separation system
MACS (Miltenyi Biotec, Bergisch Gladbach, Germany) and the
Monocyte isolation kit (Miltenyi Biotec) in accordance with the man-
ufacturer’s instructions, and the purity was 84^94% as judged by Di¡-
Quik; the remaining cells were mainly lymphocytes.
2.3. Cell culture
The human promonocytic cell line U937 was maintained in RPMI
1640 (Sigma, St. Louis, MO, USA) supplemented with 10% fetal calf
serum, 2 mM glutamine, 100 U/ml penicillin, and 100 Wg/ml strepto-
mycin. For stimulation by TNFK, isolated monocytes were resus-
pended at 5U105 cells/ml in RPMI 1640 supplemented with 5 Wg/ml
polymyxin B (Sigma) to eliminate possible e¡ects of LPS, and incu-
bated with 20 ng/ml TNFK (RpD systems, Tokyo, Japan) for 24 h;
isolated neutrophils were resuspended at 106 cells/ml in Ca2þ- and
Mg2þ-free Hanks’ balanced salt solution (HBSS) supplemented with
0.1% gelatin, and stimulated with 20 ng/ml TNFK for 2 h.
2.4. RNA isolation and quantitative RT-PCR analysis
Total RNA was extracted from 4^15U106 cells by the acid guani-
dine phenol chloroform method using Trizol (Gibco BRL, Gaithers-
burg, MD, USA). Speci¢c oligonucleotide primers were used for am-
pli¢cation of full-length CD89 and each splice variant (forward primer
(+), 5P-GTTCGTCATTGACCACATGG-3P ; reverse primer (3), 5P-
GAGGCTTCCTTGTTCAGTGC-3P [9]). The isolated RNA (1 Wg
from monocytes and neutrophils, or 2 Wg from U937 cells) was reverse
transcribed using 10 pmol of reverse primer (3), 10 U of reverse
transcriptase Superscript II (Gibco BRL), and 400 WM each dNTP
in 50 Wl of 2Ureaction bu¡er (1Ureaction bu¡er: 50 mM KCl, 10
mM Tris^HCl, pH 8.3, 1.5 mM MgCl2, and 0.01% gelatin) at 42‡C
for 30 min, followed by heating at 94‡C for 5 min. After addition of
10 pmol of primer (+) and 1 U of Taq Gold polymerase (Perkin-
Elmer, New Jersey), the sample was subjected to ampli¢cation (dena-
turation at 94‡C for 1 min, annealing at 55‡C for 1 min and extension
Fig. 1. Schematic representation of the organization of the FcKR
gene and transcripts of the full-length form (CD89) and splice iso-
forms (v66EC2 and vEC2). DNA fragments of the indicated lengths
are produced by RT-PCR using primers which correspond to the re-
gions within the EC1 and TM/C domains.
Fig. 2. PCR analysis of the FcKR transcripts in primary neutrophils and monocytes. A: Autoradiograms of the ampli¢ed products. M, a 32P-
labeled 100 bp ladder (New England Biolabs) as molecular weight marker. B: Relative amounts of the ampli¢ed products. C: The ratios of
each variant to CD89 at 20 cycles of ampli¢cation. Total RNA from neutrophils and monocytes of nine healthy individuals was analyzed by
quantitative RT-PCR. Shown in the histograms are the meanMS.E.M. of di¡erent donors. *P6 0.05.
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at 72‡C for 1 min) in 100 Wl of 1Ureaction bu¡er. PCR was per-
formed in linear conditions as shown in Fig. 2B, and unless otherwise
indicated, results at 20 cycles of ampli¢cation are shown in the ¢gures.
After adding 0.5 pmol of 5P-32P-labeled forward primer (+), the sam-
ple was further ampli¢ed once by extension at 72‡C for 5 min follow-
ing denaturation and annealing, and electrophoresed on 5% native
polyacrylamide gels. After electrophoresis, the gel was dried, and ra-
dioactivities of ampli¢ed bands were evaluated using the Image Ana-
lyzer Fujix BAS 2500A (Fuji Film, Tokyo, Japan). Statistical signi¢-
cance of the results was determined using the Student’s t-test.
Di¡erences were considered signi¢cant at P6 0.05.
3. Results and discussion
We measured the relative amount of three FcKR transcripts
using a pair of oligonucleotide primers complementary to
exons encoding the EC1 and TM/C domains, as described
previously [9] (Fig. 1). The full-length form CD89 and splice
isoforms v66EC2 and vEC2 can be detected as fragments of
528, 462 and 240 bp, respectively. We ¢rst examined cell type
speci¢city for expression of each FcKR splice variant. Total
RNA was prepared from freshly isolated blood neutrophils
and monocytes, and subjected to the quantitative RT-PCR
analysis as described in Section 2.4. As displayed in Fig.
2A,B, the amount of DNA increased proportionally at least
up to 21 cycles when 1 Wg of RNA from neutrophils and
monocytes was used. When compared under these conditions,
the ratio of vEC2 to CD89 in neutrophils is about two-fold
higher than that in monocytes, while no signi¢cant di¡erences
in the v66EC2/CD89 ratio were observed between these cell
types (Fig. 2C).
Because the results shown in Fig. 2 suggested that expres-
sion of FcKR splice isoforms is di¡erentially regulated in neu-
trophils and monocytes, we next examined expression of these
variants during myeloid di¡erentiation. Immature myeloid cell
line U937 develops into monocyte/macrophage-like phenotype
upon induction of di¡erentiation with phorbol 12-myristate
13-acetate (PMA). As shown in Fig. 3A, when U937 cells
were cultured with PMA, steady-state levels of the CD89 tran-
script increased as described previously [22]. At that time, the
extent of increase in the vEC2 transcript was smaller than
that in CD89 (Fig. 3A), which resulted in a decrease in the
ratio of vEC2 to CD89 (Fig. 3B). This is consistent with the
observation of lower vEC2 ratio in mature monocytes com-
pared with neutrophils, and suggests the involvement of vEC2
in certain cell type-speci¢c functions of FcKR. On the other
hand, we could detect no v66EC2 mRNA in this cell line.
As a ¢rst approach to address the involvement of FcKR
splice variants in myeloid functions in in£ammatory process,
we examined their expression in the presence of various in-
£ammatory cytokines, which have previously been reported to
modulate FcKR expression and functions [12^15,23]. In our
survey using U937 cells, induction of vEC2 by TNFK was
found to be signi¢cantly lower than that of CD89, while no
signi¢cant changes in the induction or downregulation levels
were observed between vEC2 and CD89 upon treatment with
IL-1L, 1-K,25-dihydroxyvitamin D3 and TGFL (Fig. 4A).
Therefore, we next examined the e¡ect of TNFK on the ratios
of splice variants to CD89 in primary neutrophils and mono-
cytes. As shown in Fig. 4B, when monocytes were incubated
with TNFK for 24 h, a signi¢cant decrease in the ratio of
vEC2 to CD89 was observed similar to that seen in U937
Fig. 3. E¡ect of PMA on expression of the FcKR splice variants in
immature myeloid cell line U937. Total RNA from U937 cells dif-
ferentiated with 100 nM PMA or vehicle (ethanol) for 72 h was an-
alyzed by quantitative RT-PCR. Data represent the meanM range of
values of two independent experiments. A: Induction of the FcKR
splice variants in response to PMA. B: E¡ect of PMA on the ratio
of vEC2 to CD89.
Fig. 4. E¡ect of in£ammatory cytokines on FcKR alternative splicing. A: Induction of vEC2 and CD89 by cytokines in U937 cells. Total
RNA from U937 cells treated with 20 ng/ml TNFK, 10 ng/ml IL-1L, 100 nM 1-K,25-dihydroxyvitamin D3 (Vit D3) and 20 ng/ml TGFL for
24 h was analyzed by quantitative RT-PCR. Data represent the meanMS.E.M. of two to seven independent experiments. *P6 0.01. B: E¡ect
of TNFK on the ratios of splice variants to CD89 in primary neutrophils and monocytes. Neutrophils and monocytes from ¢ve and four
healthy individuals, respectively, were treated with or without TNFK, and total RNA was analyzed by quantitative RT-PCR. Data represent
the meanMS.E.M. of di¡erent donors. *P6 0.05.
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cells. Conversely, 2-h treatment with TNFK increased the neu-
trophil vEC2 ratio, although such short-term treatment did
not a¡ect the monocyte vEC2 ratio (data not shown). In
addition, the opposite e¡ect of TNFK on the vEC2 ratio in
neutrophils and monocytes is unlikely to be due to di¡erences
in culture conditions, because an increased ratio in neutro-
phils in response to TNFK was also observed when RPMI
1640 medium and HBSS containing Ca2þ were used (data
not shown). In contrast, neither neutrophils nor monocytes
showed signi¢cant changes in the ratio of v66EC2 to CD89
(Fig. 4B).
Our ¢ndings indicate that induction of vEC2 by TNFK is
di¡erentially regulated in a cell type-speci¢c manner. Espe-
cially the observation of the increased vEC2 ratio in neutro-
phils could re£ect some physiological roles of this variant in
FcKR functions in this cell lineage. A recent study using poly-
saccharide-speci¢c IgA has suggested that FcKR represents an
important leukocyte receptor on neutrophils to exhibit anti-
pneumococcal cellular e¡ector function against Streptococcus
pneumoniae [24]. Moreover, enhanced expression and function
of neutrophil FcKR have recently been reported in bacteremia
including pneumonia [19]. Therefore, we isolated neutrophils
from patients with pneumonia and examined the expression of
FcKR splice transcripts. Similar to the previous report [19],
increased neutrophil FcKR expression was observed in pneu-
monia (data not shown). In addition, we found that the ratio
of vEC2 to CD89 in neutrophils of the patients was signi¢-
cantly lower compared with healthy controls, whereas no sig-
ni¢cant di¡erences in the v66EC2/CD89 ratio were observed
(Fig. 5). The higher vEC2 ratio observed in neutrophils from
healthy controls compared with the results in Fig. 2C is likely
due to aging, because we collected blood samples from older
volunteers to be matched with the patients by age (see Section
2.1). The vEC2 expression pattern in pneumonia is contrary
to the TNFK response of neutrophils in which the vEC2 ratio
increased (Fig. 4A). Chiamolera et al. [19] have reported that
although serum TNFK levels increase in patients with bacter-
emia, this does not signi¢cantly correlate with increased FcKR
levels observed in these patients. Therefore, the mechanism
underlying a decrease of the vEC2/CD89 ratio in pneumonia
might involve a factor(s) in addition to or other than TNFK.
At present, the function of vEC2 is unknown. We and
others have previously demonstrated the physical association
of FcKR with the FcRQ subunit [25^28], which contains a
common ITAM (immunoreceptor tyrosine-based activation
motif) in its cytoplasmic tail and is essential for signaling
through FcKR [25,27]. Based on the molecular structure, the
vEC2 protein, which lacks a part of the extracellular portion,
is thought to be capable of associating with FcRQ, because
FcRQ interacts with FcKR through the FcKR transmembrane/
cytoplasmic domains [27]. Therefore, one can speculate that
vEC2 competes with the full-length CD89 for FcRQ. In this
context, Launay et al. [29] have recently demonstrated that
FcKR is expressed with or without FcRQ on monocytes and
neutrophils, and FcRQ-associated and FcRQ-less FcKRs have
di¡erent functions. Moreover, Chiamolera et al. [19] have
shown that the FcKR molecule whose expression increases
in bacteremia is the FcRQ-associated form. Therefore, the de-
creased vEC2 ratio in pneumonia observed in Fig. 5 may lead
to an increase in FcRQ-associated FcKR through relieving
competition for FcRQ. In addition, although the EC1 domain
rather than the EC2 domain has been identi¢ed as the IgA-
binding domain of FcKR [30,31], Pleass et al. [8] have shown
that the vEC2 protein cannot bind serum IgA. In this context,
the vEC2 variant might act as a dominant negative form of
FcKR and selectively a¡ect serum IgA-triggered FcKR func-
tions. The results presented in Fig. 4 showing opposite e¡ects
of TNFK on the monocyte and neutrophil vEC2/CD89 ratios
may re£ect the switching of serum IgA-responsive cells from
neutrophils to monocytes during the in£ammatory process.
In conclusion, we suggested in this study that expression of
the FcKR splice isoform vEC2 but not v66EC2 is di¡eren-
tially regulated in a cell type-speci¢c manner and in response
to in£ammatory and/or infectious processes. FcKR splice iso-
forms with deletion at the EC2 domain could represent a
physiological mechanism to generate its functional diversity
in di¡erent cell types, which has a critical role in IgA-medi-
ated host defense.
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